Kristen Hallam on Muck Rack

Kristen Hallam Verified

Covers:  science, health policy, biotechnology, mergers & acquisitions, health, pharmaceutics
Doesn't Cover: clinical trial initiation, new product launches

@BloombergNews health editor in London. @NorthwesternU alum, @AHCJ member. Email: khallam@bloomberg.net. RTs & links not endorsements.

IMS Health to buy Quintiles in $9B pharma deal

IMS Health to buy Quintiles in $9B pharma deal
sltrib.com — IMS Health tracks prescriptions, medical claims and electronic records and sells the data, while Quintiles offers a range of services focused on product development, including advice on clinical-trial design -- a business called a contract research organization, or CRO.

IMS Health to buy Quintiles in $9 billion pharma data deal

IMS Health to buy Quintiles in $9 billion pharma data deal
lifehealthpro.com — (Bloomberg) - IMS Health Holdings Inc. (NYSE:IMS) will buy Quintiles Transnational Holdings Inc. (NYSE:Q) in an all-stock transaction for about $9 billion, bringing together two of the biggest providers of data and services for the pharmaceutical industry.

IMS Health to Merge With Quintiles in $23 Billion Deal

bloomberg.com — IMS Health Holdings Inc. agreed to merge with Quintiles Transnational Holdings Inc. to expand in services and products for clinical trial design, in an all-stock transaction with an enterprise value of more than $23 billion.

Ackman to Testify With Pearson at Senate Drug-Pricing Hearing

Ackman to Testify With Pearson at Senate Drug-Pricing Hearing
bloomberg.com — Bill Ackman, the billionaire activist investor, will testify before a Senate panel Wednesday on prescription-drug pricing as lawmakers probe practices at troubled Valeant Pharmaceuticals International Inc. Valeant's outgoing Chief Executive Officer Mike Pearson and board member Howard Schiller will join Ackman, whose Pershing Square Capital Management LP has become one of Valeant's biggest holders.

Pfizer, Allergan $160 billion deal killed by U.S. tax rules

Pfizer, Allergan $160 billion deal killed by U.S. tax rules
lifehealthpro.com — (Bloomberg) - Pfizer Inc. (NYSE:PFE) and Allergan PLC (NYSE:AGN) have terminated their $160 billion merger in an abrupt end to the largest-ever health-care deal after the U.S. government cracked down on corporate tax inversions. The U.S. Treasury Department's proposed new rules to deter companies from using acquisitions to shift their tax addresses overseas drove the decision, the companies said Wednesday in a statement.

Accounting Today

Accounting Today
accountingtoday.com — (Bloomberg) Pfizer Inc. and Allergan Plc have terminated their $160 billion merger in an abrupt end to the largest-ever health-care deal after the U.S. government cracked down on corporate tax inversions. The U.S. Treasury Department's proposed new rules to deter companies from using acquisitions to shift their tax addresses overseas drove the decision, the companies said Wednesday in a statement.

Pfizer, Allergan end $160B merger amid new tax rules

Pfizer, Allergan end $160B merger amid new tax rules
pbn.com — LONDON - Pfizer Inc. and Allergan PLC agreed to terminate their $160 billion merger, an abrupt end to the largest-ever health-care acquisition as officials in Washington crack down on corporate inversions. The U.S. Treasury Department's proposed new rules to deter inversions drove the decision, the companies said Wednesday in a statement.

Allergan Weighs Return to Deals With $34 Billion From Teva Sale

bloomberg.com — The end of the health-care industry's biggest ever merger may also be the beginning of another round of deal-making for Allergan Plc. "We will look at anything that is a growth-oriented asset," Allergan Chief Executive Officer Brent Saunders said in a Bloomberg Television interview Wednesday, declining to specify potential targets.

Pfizer Confirms Termination of Proposed $160 Billion Allergan Merger

bloomberg.com — Pfizer Inc. and Allergan Plc agreed to end their $160 billion merger, terminating the largest-ever health-care acquisition as officials in Washington crack down on corporate inversions. The decision was driven by the actions announced by the U.S. Treasury Department on Monday, the companies said Wednesday in a statement.

Shire Gives CEO 422% Pay Boost to Allay Defection Concerns

bloomberg.com — Shire Plc boosted Flemming Ornskov's compensation five-fold last year to allay concern the chief executive might be wooed away by a rival following his "exceptional performance." Ornskov's total compensation rose to $21.6 million last year, Dublin-based Shire said in its annual report Tuesday. That includes $16.8 million in long-term incentive awards.
More Articles →
May 05, 2016

RT @matthewherper: Read this LAT expose on OxyContin. Drop everything and read it now. twitter.com/thegarance/sta…

May 05, 2016

Sanofi letter to Medivation escalates tension after rejection of $9.3 bln offer bloom.bg/23rH2QT via @business $MDVN $SNY

May 05, 2016

RT @FayCortez: Call me a slow adopter but I'm just hearing how PR folks are being taught to pitch reporters on Twitter. Does this EVER work? Can't imagine.

May 05, 2016

In the reasons to leave London category, I present this: twitter.com/ManusCranny/st…

May 04, 2016

Hearing-Aid Maker Sonova to Buy AudioNova for $950 Million bloom.bg/26S6X8G via @business

May 03, 2016

RT @ElyseTanouye: Shkreli's Lawyers Say Turing Founder May Face More Charges bloom.bg/1SKU2fc via @business

May 03, 2016

RT @ArmstrongDrew: So, how long until Biogen's hemophilia business gets snapped up by a buyer, like Baxalta was? bloomberg.com/news/articles/…

May 03, 2016

RT @helenwsj: So what is read-across from $BIIB getting out of hemophilia for Shire/Baxalta? Doesn't seem terribly good. $SHPG


Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.